ADIPOQ and prostate carcinoma: The combined clinical significance of adiponectin and leptin in prostate cancer patients has been studied in various contexts, including the risk of prostate carcinogenesis risk [30], patient obesity and abnormal glucose metabolism [31,32,33], adipokine expression in prostate tissue [34], and correlation with cardiovascular disease [35].